Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

immatics Appoints Dr Rainer Kramer as CBO

Published: Thursday, April 12, 2012
Last Updated: Thursday, April 12, 2012
Bookmark and Share
Dr. Kramer will lead immatics’ business development unit.

immatics biotechnologies GmbH has announced the appointment of Dr. Rainer Kramer as Chief Business Officer (CBO) with immediate effect.

In this newly created role, Dr. Kramer will lead immatics’ Business Development Unit in order to create optimal value from the Company’s pipeline of therapeutic cancer vaccines.

Dr. Kramer has many years of business development experience within the pharmaceutical industry. He joins from Signature Diagnostics, an oncology diagnostics company where he was CBO.

Before that, he was Vice President Business Development at Jerini AG, where he was responsible for all licensing, partnering, and alliance management activities, and played a key role in the sale of the Company to Shire in 2008.

Before joining Jerini, he held various business development and research positions at MorphoSys AG, Martinsried, and Amgen Inc.

Dr. Kramer holds a Diploma in Molecular Biology from the University of Regensburg and a PhD from the Max-Planck-Institute for Neurobiology.

“Rainer’s appointment is a further important step in advancing our business strategy aimed at maximizing the potential of our TUMAP-based therapeutic cancer vaccine pipeline”, said Paul Higham, CEO of immatics.

Higham continued, “The positive clinical results that we have already generated with our lead products IMA901, for advanced renal cancer, and IMA910, for advanced colorectal cancer, highlight our potential to make a real difference to the management of these difficult to treat cancers. Rainer’s strong business and deal-making experience will be a great asset as we seek partners where appropriate to help us to progress our vaccine candidates to market.”

Rainer Kramer said: “The impressive data with IMA901 and IMA910 confirm the tremendous potential of this novel class of therapeutic vaccines. I am delighted to be joining immatics at such an exciting time and look forward to making a significant contribution to the successful implementation of the Company’s corporate strategy, which is expected to deliver significant shareholder value and much improved treatment options for cancer patients.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

immatics and BioNTech to Advance a Novel Class of Fully Personalized Therapeutic Cancer Vaccines
Regulatory authority approves clinical trial for Glioma Actively Personalized Vaccine Consortium (GAPVAC).
Thursday, October 16, 2014
immatics Receives €22 Million Final Tranche of Series D Fundraising
Funds will be used to complete phase 3 study with IMA901 and to invest in the expansion of immatics’ Human Immunopeptidome Program to identify the most relevant targets for cancer immunotherapies.
Thursday, July 17, 2014
Immatics to Continue Work on Vaccine (IMA950) for Glioblastoma
A new cancer vaccine (IMA950) for glioblastoma has met the two primary endpoints of safety and immunogenicity in a trial conducted by Cancer Research UK.
Thursday, April 24, 2014
immatics Closes €34 Million Financing
immatics’ lead cancer vaccine IMA901 to report interim phase 3 data in 2014 and final data in 2015.
Tuesday, October 15, 2013
Professor Dr Hans-Georg Rammensee Awarded the Bayer Hansen Family Award 2013
Prestigious Hansen Family Award recognizes Hans-Georg Rammensee’s pioneering scientific research activities.
Friday, March 08, 2013
immatics Presents Encouraging Overall Survival Data from a Phase 2 Study in CRC
T-cell responses to the IMA910 colorectal cancer vaccine peptides show a clear correlation with longer overall survival.
Monday, June 04, 2012
immatics Wins 2012 TiE50 Award
immatics chosen as a leading company in the life sciences category by the world's largest entrepreneurial network.
Friday, May 25, 2012
immatics Presents Positive Phase II Results with IMA910 in CRC Patients
Study shows a consistent association between immune response to IMA910 and all clinical endpoints and an excellent tolerability profile.
Wednesday, January 25, 2012
Scientific News
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Genes That Increase Children's Risk Of Blood Infection Identified
A team led by Oxford University has identified genes that make certain children more susceptible to invasive bacterial infections by performing a large genome-wide association study in African children.
Poverty Marks a Gene, Predicting Depression
New study of high-risk teens reveals a biological pathway for depression.
World’s Largest Coral Gene Database
‘Genetic toolkit’ will help shed light on which species survive climate change.
Early Genetic Changes in Premalignant Colorectal Tissue Identified
Findings point to drivers of early cancer development, targets for cancer prevention therapies.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Modified Microalgae Converts Sunlight into Valuable Medicine
A special type of microalgae can soon produce valuable chemicals such as cancer treatment drugs and much more just by harnessing energy from the sun.
Breakthrough Approach to Breast Cancer Treatment
Scripps scientists have designed a drug candidate that decreases growth of breast cancer cells.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!